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Background: Sterol regulatory element binding protein-1c (SREBP-1c) is a regulator of the lipogenic pathway and is
transcriptionally activated by liver X receptor α (LXRα). This study aims to investigate phytochemicals inhibiting the
autonomous transactivity of LXRα with potentials as SREBP-1c inhibitors. Licochalcone A (LicA) is a flavonoid isolated
from licorice root of Glycyrrhiza plant.
Methods: The effects of 238 natural chemicals on autonomous transactivity of LXRα were determined by the
Gal4-TK-luciferase reporter system. The inclusion criteria for chemical selection was significant (P < 0.05) inhibition
of autonomous transactivity of LXRα from three independent experiments. Transcript levels of mouse primary
hepatocytes were measured by conventional or quantitative RT-PCR. Luciferase assay was used to assess synthetic
or natural promoter activities of LXRα target genes. The effect of LicA on lipogenic activity was evaluated by
measuring cellular triglycerides in mouse primary hepatocytes. The recruitment of RNA polymerase II to the LXR
response element (LXRE) region was examined by chromatin immunoprecipitation.
Results: Among 238 natural compounds, LicA considerably inhibited the autonomous transactivity of LXRα and
decreased the LXRα-dependent expression of SREBP-1c. LicA inhibited not only LXRα-dependent activation of the
synthetic LXRE promoter but also that of the natural SREBP-1c promoter. As a consequence, LicA reduced the
LXRα agonist-stimulated transcription of several lipogenic genes. Furthermore, LXRα-dependent hepatic lipid
accumulation was repressed by LicA in mouse primary hepatocytes. Interestingly, the LXRα-dependent activation of
ATP-binding cassette transporter A1 (ABCA1) and ATP-binding cassette transporter G1 (ABCG1), other LXR target
genes involved in reverse cholesterol transport (RCT), was not inhibited by LicA. LicA hindered the recruitment of
RNA polymerase II to the LXRE of the SREBP-1c gene, but not of the ABCA1 gene.
Conclusions: LicA is a selective inhibitor of LXRα, repressing lipogenic LXRα target genes but not RCT-related LXRα
target genes.Background
Enzymes involved in lipogenesis, such as acetyl CoA carb-
oxylase (ACC), fatty acid synthase (FAS), stearoyl-CoA
desaturase 1 (SCD1), long-chain elongase, and glycerol-3-
phosphate acyltransferase (GPAT) [1-7], can be rapidly
controlled by posttranslational and/or allosteric mecha-
nisms, but are mostly regulated on a long-term basis at* Correspondence: swkim7@amc.seoul.kr
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gulatory element binding protein-1c (SREBP-1c) [8,9].
SREBP-1c is a transcription factor of the basic-helix-
loop-helix-leucine zipper family and is a regulator of the
lipogenic pathway [10,11]. Transcription of the above-
mentioned lipogenic enzymes is augmented by SREBP-1c
activation [8,10].
SREBP-1c appears to be the main regulator of lipoge-
nesis in the liver but not in adipose tissue, as shown by a
reduction in lipogenic enzymes in the liver but not in
adipose tissue following SREBP-1c knockout [12]. In
contrast to lipogenesis in adipose tissue, increased he-
patic lipogenesis has many harmful effects, leading tos is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Additionally, hepatic lipogenesis strongly correlated with
insulin resistance [14,15]. Therefore, modulation of hep-
atic SREBP-1c activity could be exploited to treat such
metabolic diseases.
SREBP-1c is transcriptionally activated by liver X receptor
α (LXRα), which is a transcription factor belonging to the
nuclear receptor family [16]. LXRα is also an important
regulator of lipogenesis, as it directly regulates other
lipogenic genes such as ACC, FAS, and SCD1, as well as
SREBP-1c, and is associated with hepatic steatosis [17-19].
Thus, LXRα inhibitors could inhibit more lipogenic genes
than SREBP-1c inhibitors.
In addition to lipogenic genes, LXRα regulates reverse
cholesterol transport (RCT)-related genes including ATP-
binding cassette transporter A1 (ABCA1) and ATP-binding
cassette transporter G1 (ABCG1). In terms of metabolic
disease, lipogenesis is considered harmful for fatty liver
diseases, whereas RCT is considered beneficial for athero-
sclerosis. More specifically, while LXR agonists possess
potent antiatherosclerotic effects, they cannot be used for
antiatherosclerotic therapy because of lipogenic adverse
effects. Thus, the selective regulation of LXR target genes
is crucial as a therapeutic approach.
This study aims to investigate phytochemicals with in-
hibitory activity against the autonomous transactivity of
LXRα for identifying SREBP-1c inhibitors. The selected




Two hundred and thirty-eight natural plant chemicals were
provided by Dr. Won Keun Oh (Korea Bioactive Natural
Material Bank, Seoul National University, Seoul, South
Korea). T0901317 and dimethyl sulfoxide (DMSO) were
purchased from Sigma-Aldrich (St. Louis, MO, USA).
Percoll was purchased from GE Healthcare (Pittsburgh,
PA, USA). M199 medium was obtained from Gibco
(Grand Island, NY, USA). Dulbecco’s Modified Eagle’s
Medium (DMEM) and fetal bovine serum (FBS) were
products of Hyclone (Logan, UT, USA).
Preparation of mouse primary hepatocytes and
cell culture
Mouse primary hepatocytes were prepared from 8–10-
week-old male C57BL/6 mice (Orient Bio, Seongnam,
South Korea) using a previously described collagenase per-
fusion procedure with minor modifications [20]. Briefly,
the liver was perfused with Mg2+/Ca2+-free Hank’s ba-
lanced salt solution (Sigma-Aldrich) containing 100 U/mL
collagenase type II (Gibco) and 48 μg/mL trypsin inhibitor
(Sigma-Aldrich). Next, viable hepatocytes were harvested
using Percoll density gradient centrifugation after filteringthrough a 100-μm nylon mesh (BD Biosciences, San Jose,
CA, USA). Isolated primary hepatocytes were plated onto
collagen type I-coated culture dishes and maintained in
M199 media. Human hepatoma HepG2 cells were main-
tained in DMEM containing 10% FBS at 37°C in a humi-
dified 5% CO2 incubator. All animal protocols were
approved by the Institutional Animal Care and Use Com-
mittee (IACUC) of the Asan Institute for Life Sciences,
Asan Medical Center (Approval No. 2013-12-168). Mice
were maintained in a temperature-controlled facility with
a 12 h light/12 h dark cycle and provided ad libitum ac-
cess to water and regular rodent chow diet. Following
acclimatization for 1 week, the mice were sacrificed for
the preparation of primary hepatocytes.Transfection and luciferase reporter assay
HepG2 cells were plated into 24-well plates 24 h prior to
transfection and grown in DMEM supplemented with 10%
charcoal-stripped FBS. Transfections were performed with
Gal4-TK-luciferase, Gal4-hLXRα ligand binding domain
(LBD), 3 × LXRE-luciferase, SREBP-1c LXRE-luciferase,
ABCA1 LXRE-luciferase, or ABCG1 LXRE-luciferase using
Lipofectamine 2000 reagent (Invitrogen, Grand Island, NY,
USA) according to the manufacturer’s protocol. After 24 h,
the cells were treated with 1 μM of the LXR agonist
T0901317 and 10 μg/mL of natural compounds for 18 h.
Luciferase activity was then measured using a Centro LB
960 luminometer (Berthold Technology, Bad Wildbad,
Germany), and enzyme activity values were normalized to
β-galactosidase levels. For normalization, pActin-βgal plas-
mids were cotransfected into hepatocytes along with the
promoter-luciferase reporter genes. The inclusion criteria
for chemical selection was significant (P < 0.05) inhibition
of autonomous transactivity of LXRα from three indepen-
dent experiments.Analysis of transcript levels by conventional or
quantitative RT-PCR
Total RNA was extracted from primary hepatocytes by
Trizol-RNA Lysis Reagent (Invitrogen) according to the
manufacturer’s protocol. Purified RNA was reverse tran-
scribed using M-MLV reverse transcriptase (Promega,
Madison, WI, USA). Next, specific mRNA levels were
analyzed by conventional or quantitative RT-PCR. The
oligonucleotide primers used for conventional RT-PCR
were as follows: SREBP-1c, 5′-GGC GCA TGG ATT
GCA CAT TT-3′ and 5′-GCA GGC TGT AGG ATG
GTG A-3′; ABCA1, 5′-ACA AAG AGC TGG AGC
GAC AT-3′ and 5′-CAG CCA ACT CCT GAA AGG
TC-3′; and 18S rRNA, 5′-CGT CCC CCA ACT TCT
TAG AG-3′ and 5′-CAC CTA CGG AAA CCT TGT
TAC-3′. 18S rRNA was used as an internal control in
conventional RT-PCR.
Figure 1 Effects of phytochemicals on (A) the autonomous Gal4-hLXRα
LBD transactivity and (B) the LXRα agonist-stimulated transcript levels
of SREBP-1c. (A) Gal4-LXRα LBD transactivity was measured in the
presence of 1 μM T0901317 and 10 μg/mL natural compounds by a
Gal4-TK- luciferase assay. Data were presented as means (SD) from
three independent experiments with duplicate determinations.
(B) Effects of natural compounds on T0901317-stimulated SREBP-1c
mRNA levels in primary hepatocytes. mRNA levels were measured by
conventional RT-PCR. Quantitation of band intensities was performed
using ImageJ (NIH, Bethesda, MD, USA). Data are presented as means
(SD) from three independent experiments. Statistical analysis was
performed using one-way ANOVA. P* = P value for Bonferroni correction.
T1317, T0901317; War, warangalone 4′-methyl ether; LicA, licochalcone
A; SigK, sigmoidin K; Alb, albaspidin P-P; Cur, curcumin; Vin, ɛ-viniferin;
Mac, macelignan.
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on a LightCycler 480 system (Roche, Basel, Switzerland).
The following oligonucleotide primers were used for
quantitative RT-PCR: SREBP-1c, 5′-CAG CCA TGG
ATT GCA CAT TTG-3′ and 5′-GTC TTG GTT GTT
GAT GAG CTG G-3′; FAS, 5′-CTG CAG CTG TCA
GTG TGA AGA AG-3′ and 5′-GCA GCA TTT TTA
CCA GGT TGG T-3′; SCD1, 5′-AGC TCA GTC TCA
CTC CTT CCC TTA-3′ and 5′-CAG CCA GCC TCT
TGA CTA TTC C-3′; GPAT, 5′-TCA TCC AGT ATG
GCA TTC TCA CA-3′ and 5′-GCA AGG CCA GGA
CTG ACA TC-3′; ABCA1, 5′-GAC CCG TAC TCT
CGC AGG G-3′ and 5′-CCT TGC CGG TAT TTT
AGC AGG-3′; ABCG1, 5′-TTC ATC GTC CTG GGC
ATC TT-3′ and 5′-GAA ATA GGC GAT GAG CCG C-3′;
and ribosomal protein S29, 5′-CGC AAA TAC GGG
CTG AAC A-3′ and 5′-GCC TAT GTC CTT CGC GTA
CTG-3′. Ribosomal protein S29 was used as an internal
control for quantitative RT-PCR.
Cellular triglyceride (TG) accumulation
Primary hepatocytes were plated onto 60-mm collagen-
coated culture dishes, incubated overnight in M199
medium, and treated with 1 μM T0901317 and 10 μg/mL
LicA for 24 h. After treatment, the cells were washed
twice with cold phosphate buffered saline (PBS), lysed in
PBS containing 1% Triton X-100 for 30 min at 4°C, and
centrifuged (Micro 17TR, Hanil Science Industrial, South
Korea) at 10,000 × g for 10 min at 4°C. Cellular lipids were
then extracted from the supernatant by the Bligh and Dyer
method [21]. TG levels were determined by a TG assay kit
(Asan Pharmaceutical, Gyeonggi-do, South Korea) and
normalized to total protein levels.
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed on primary hepatocytes
treated with 1 μM T0901317 and 10 μg/mL selected com-
pound for 30 min, as described previously, with minor
modifications [22]. Briefly, cells were fixed with 1% for-
malin (Sigma-Aldrich) for 20 min and then quenched with
0.125 M glycine for 5 min at room temperature. The cells
were washed twice with cold PBS and lysed in SDS lysis
buffer containing 50 mM Tris-HCl (pH 8.0), 10 mM
EDTA, and 1% SDS. Soluble chromatin was prepared
by sonication (VCX-600 sonicator, Sonics & Materials,
Newton, CT, USA) and then pre-cleared by protein
G-agarose beads (Santa Cruz Biotechnology, Santa Cruz,
CA, USA). Pre-cleared supernatants were then immuno-
precipitated with anti-RNA polymerase II (Santa Cruz
Biotechnology) or IgG antibodies (Abcam, Cambridge,
UK) for 12 h at 4°C. The final DNA extracted from the
immunoprecipitate was analyzed by quantitative RT-PCR
using the LightCycler 480 system (Roche). The oli-
gonucleotide primers used for the ChIP assay were asfollows: SREBP-1c LXRE region, 5′-AGG CTC TTT TCG
GGG ATG G-3′ and 5′-TGG GGT TAC TGG CGG TCA
C-3′; and ABCA1 LXRE region, 5′-GGG GAA AGA
GGG AGA GAA CAG-3′ and 5′-GAA TTA CTG GTT
TTT GCC GC-3′. Immunoprecipitated DNA levels were
presented as fold enrichments normalized to 10% input
DNA levels.
Statistical analysis
Quantitative values were presented as means (SD). Sta-
tistical analysis was performed using one-way ANOVA
(SPSS19, IBM, Chicago, IL, USA). For post-hoc analysis,
Fisher’s LSD (least significant difference) test was con-
ducted. Bonferroni method was used to correct P values
for multiple comparisons. Differences with P values less
than 0.05 were considered statistically significant.
Figure 2 Effects of LicA on the T0901317-stimulated activation of
LXRE-containing promoters. LXRα-mediated transcriptional activity was
determined on (A) 3 × LXRE-luciferase or (B) SREBP-1c LXRE-luciferase
reporters in the presence of 1 μM T0901317 and 10 μg/mL LicA in
HepG2 cells. Luciferase activity was normalized to cotransfected
β-galactosidase activity. Data were presented as means (SD) from four
independent experiments with duplicate determinations. Statistical
analysis was performed using one-way ANOVA. P* = P value for Bonferroni
correction. DMSO, dimethyl sulfoxide; T1317, T0901317.
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LicA inhibits the autonomous transcriptional activity of
LXRα and LXRα-stimulated expression of SREBP-1c
Two hundred and thirty-eight compounds isolated from
various plants were tested in a Gal4-dependent trans-
activation assay by Gal4-hLXRα LBD. Licochalcone AFigure 3 Effects of LicA on (A) the LXRα-stimulated expression of lipogeni
(A) T0901317-induced expression of SREBP-1c, SCD1, FAS, and GPAT was d
presented as means (SD) from four independent experiments with triplicat
T0901317 and LicA. Intracellular TG levels were measured enzymatically after
LicA and normalized to total protein levels. Data were presented as means (S
Statistical analysis was performed by one-way ANOVA. P* = P value for Bonfer(LicA) showed strong inhibitory activity against the
autonomous transactivity of LXRα (Figure 1A). Because
SREBP-1c is a regulator of lipogenesis and an LXRα
target, we then investigated the effects of these plant-
derived compounds on the transcript levels of SREBP-1c
to determine the antilipogenic effect of LicA. LicA also
repressed LXRα agonist T0901317-stimulated transcrip-
tion of SREBP-1c (Figure 1B).
LicA directly modulates the promoter activity of synthetic
LXRE and SREBP-1c LXRE reporters
To confirm the inhibitory effects of LicA against LXRα
activity in the context of the LXRE promoter without
coercive DNA binding of Gal4-hLXRα LBD via the Gal4
DNA binding domain, we determined the T0901317-
stimulated activity of LXRE-containing reporter genes in
the presence of LicA. LicA inhibited not only T0901317-
dependent LXR activation of the synthetic 3 × LXRE
reporter (Figure 2A), but also of the natural SREBP-1c
promoter (Figure 2B). These results indicated that LicA
directly modulated transcriptional activation of the
SREBP-1c gene via LXRE.
LicA inhibits the LXRα-dependent expression of lipogenic
genes and TG accumulation in primary hepatocytes
Because both LXRα and SREBP-1c activation enhance
the transcription of many lipogenic genes, we examined
the effects of LicA on the transcript levels of variousc genes and (B) TG accumulation in mouse primary hepatocytes.
etermined in the presence or absence of LicA by qRT-PCR. Data were
e determinations. (B) TG accumulation in response to cotreatment with
treatment of primary hepatocytes with 1 μM T0901317 and 10 μg/mL
D) from four independent experiments with duplicate determinations.
roni correction. DMSO, dimethyl sulfoxide; T1317, T0901317.
Figure 4 Effects of LicA on (A) the LXRE-containing promoter activity
of ABCA1 and ABCG1 genes and (B) the T0901317-stimulated mRNA
levels of ABCA1 and ABCG1. (A) The activity of ABCA1 LXRE-luciferase
or ABCG1 LXRE-luciferase was determined, following treatment with
1 μM T0901317 and 10 μg/mL LicA, in HepG2 cells and normalized to
cotransfected β-galactosidase activity. Data were presented as means
(SD) from four independent experiments with duplicate determinations.
(B) The mRNA levels of ABCA1 and ABCG1 were measured in primary
hepatocytes treated with 1 μM T0901317 and 10 μg/mL LicA by
qRT-PCR. Data were presented as means (SD) from 4 independent
experiments with triplicate determinations. Statistical analysis was
performed by one-way ANOVA. P* = P value for Bonferroni correction.
DMSO, dimethyl sulfoxide; T1317, T0901317.
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RT-PCR. LicA substantially repressed the T0901317-
induced expression of SREBP-1c, FAS, SCD1, and GPAT
(Figure 3A). SREBP-1c, FAS, and SCD1 are LXRα target
genes, while FAS, SCD1, and GPAT are SREBP-1c target
genes. Subsequently, cellular lipids were extracted and an-
alyzed to determine whether LicA treatment altered the
intracellular accumulation of TGs following LXRα activa-
tion. Quantitative analysis showed that LicA significantly
reduced T0901317-stimulated TG accumulation in pri-
mary hepatocytes (Figure 3B). These results suggested that
the inhibitory effects of LicA on LXRE-containing pro-
moters decreased TG synthesis in primary hepatocytes.
LicA does not inhibit the promoter activity and
transcription of RCT-related LXRα target genes
LXRα activation stimulates not only lipogenic genes, but
also RCT-related genes such as ABCA1 and ABCG1
[23-25]. RCT is a process that transports cholesterol
from peripheral tissues to the liver for excretion in the
bile, improving metabolic diseases such as atheroscle-
rosis. ABCA1 functions as the gatekeeper of the RCT
process for eliminating excess cholesterol and has a
major impact on cellular and whole body cholesterol
metabolism [26]. ABCG1 also plays an important role in
RCT in vivo by promoting cholesterol efflux onto lipi-
dated apoA-I [24]. Therefore, we examined the effects of
LicA on the promoter activity of ABCA1 and ABCG1
genes. LicA did not affect LXRα-dependent activation of
ABCA1 and ABCG1 promoters (Figure 4A). To confirm
this selective activity of LicA, we analyzed the effects of
LicA on the transcript levels of ABCA1 and ABCG1 in
the presence of T0901317 by quantitative RT-PCR. Con-
sistent with the promoter assay, T0901317-dependent
increases in ABCA1 and ABCG1 gene transcription
were not repressed by LicA (Figure 4B).
LicA selectively reduces the recruitment of RNA
polymerase II to SREBP-1c LXRE, but not to ABCA1 LXRE
To elucidate the mechanism underlying the selective ac-
tivity of LicA, we compared the recruitment of RNA
polymerase II to the LXRE region of the SREBP-1c gene
with that of the ABCA1 gene by a ChIP assay. In line
with the previous results, the recruitment of RNA poly-
merase II to the LXRE region was inhibited on the
SREBP-1c gene by LicA, but not on the ABCA1 gene
(Figure 5). These results suggested that LicA inhibited
SREBP-1c expression and lipid accumulation by selec-
tively reducing the recruitment of RNA polymerase II to
the LXRE region of the SREBP-1c gene.
Discussion
LicA was identified to be an LXRα inhibitor in this study.
LicA is one of the reversely constructed chalcones or“retrochalcones” (licochalcone A–E, echinatin) that are
isolated and characterized from licorice, the root and stolon
of the Glycyrrhiza plant (Leguminosae) (e.g., Glycyrrhiza
glabra or Glycyrrhiza inflata) [27-29]. It has been de-
monstrated that LicA has anti-inflammatory [30,31],
antiparasitic [32], antifungal [33], anticancer [34,35], and
osteogenic activities [36]. Recently, Quan et al. [37] re-
ported that LicA inhibited SREBP-1c and its target genes
via indirect activation of AMP-activated protein kinase
and showed antilipogenic effects in the liver. Based on our
current results, we suggested that LicA also directly inhi-
bited SREBP-1c transcription in hepatocytes.
Transcription of SREBP-1c is activated by insulin in
the liver through the combinatorial actions of SREBP,
Figure 6 Schematic diagram of selective inhibition of lipogenic
pathway by LicA. Combination therapy of LicA and T0901317 could
improve atherosclerosis without lipogenic adverse effects.
Figure 5 Effects of LicA on the recruitments of RNA polymerase II to
the LXRE regions of SREBP-1c (A) and ABCA1 (B) genes. After treatment
of primary hepatocytes with 1 μM T0901317 and 10 μg/mL LicA, ChIP
assays were performed using anti-RNA polymerase II or IgG antibodies.
Immunoprecipitated LXRE-containing DNA levels were determined by
qRT-PCR and normalized to input DNA. Data were presented as means
(SD) from four independent experiments with triplicate determinations.
Statistical analysis was performed by one-way ANOVA. P* = P value for
Bonferroni correction. DMSO, dimethyl sulfoxide; T1317, T0901317.
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Among these factors, LXR plays a central role in the
insulin-mediated activation of SREBP-1c and subsequent
stimulation of fatty acid synthesis [17]. In the present
study, LicA was initially selected for its inhibitory effect
against autonomous transactivity of LXRα. Further in-
vestigation showed that LicA acted directly on the LXRE
of the SREBP-1c gene. LicA inhibited the recruitment of
RNA polymerase II to the LXRE region of the SREBP-1c
gene, thus repressing LXRα-dependent expressions of
SREBP-1c and its target genes related to lipogenesis. All
these actions together resulted in diminished accumula-
tion of TG in primary hepatocytes following treatment
with T0901317.
The inhibition of LXRα-mediated transcription by
LicA was selective for lipogenic process (Figure 6). It is
well known that LXRα regulates both lipogenic genesand RCT-related genes by direct binding to their LXREs
[18,39,40]. Nevertheless, LicA selectively inhibited the
transcription of the lipogenic SREBP-1c gene, but did not
repress the LXRα-stimulated transcription of RCT-related
genes including ABCA1 and ABCG1. The recruitments of
RNA polymerase II to the LXREs were differentially regu-
lated by LicA between SREBP-1c and ABCA1 promoters.
ABCA1 and ABCG1 promote cellular cholesterol efflux
synergistically. The efflux of cholesterol and phospholipids
to apoA-I mediated by ABCA1 converts apoA-I into nas-
cent high density lipoprotein, which can then act as an
efficient acceptor for ABCG1-mediated cholesterol efflux,
followed by formation of mature HDL particles [41-43].
Hence, the selective inhibitory activity of LicA against the
lipogenic pathway could be therapeutically beneficial for
the treatment of metabolic diseases. Further investigation
is required to identify the factor by which the recruitments
of RNA polymerase II to LXREs are different between
SREBP-1c and ABCA1 promoters. It is a noteworthy fact
that SREBP-1c and ABCA1 are differently regulated in
LXR-/- macrophages through the promoter-specific roles
of LXR/corepressor complexes [44].Conclusion
LicA is a selective inhibitor of LXRα, repressing lipo-
genic LXRα target genes but not RCT-related LXRα tar-
get genes.
Abbreviations
ABCA1: ATP-binding cassette transporter A1; ABCG1: ATP-binding cassette
transporter G1; ACC: Acetyl-CoA carboxylase; ChIP: Chromatin immunoprecipitation;
FAS: Fatty acid synthase; GPAT: Glycerol-3-phosphate acyltransferase;
LicA: Licochalcone A; LXRα: Liver X receptor α; LXRE: LXR response element;
RCT: Reverse cholesterol transport; SCD1: Stearoyl-CoA desaturase 1;
SREBP-1c: Sterol regulatory element binding protein-1c; TG: Triglyceride.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SWK designed the study and wrote the manuscript. GSO, GGL and JY
performed the experiments. WKO analyzed the data. All authors have read
and approved the final version of the manuscript.
Oh et al. Chinese Medicine  (2015) 10:8 Page 7 of 8Acknowledgements
This study was supported by a grant (A084335) from the Korea Healthcare
Technology R&D Project, Ministry for Health, Welfare & Family Affairs,
Republic of Korea; by a grant (NRF-2006-2005402) from the National
Research Foundation of Korea Grants funded by the Korean Government;
and by intramural grants (2009-352 and 2010-352) from the Asan Institute for
Life Sciences, Seoul, Korea to SWK.
Author details
1Department of Pharmacology, Asan Medical Center, University of Ulsan
College of Medicine, Seoul 138-736, Korea. 2Bio-medical Institute of
Technology, University of Ulsan College of Medicine, Seoul 138-736, Korea.
3Korea Bioactive Natural Material Bank, College of Pharmacy, Seoul National
University, Seoul 151-742, Korea.
Received: 19 September 2014 Accepted: 13 April 2015
References
1. Towle HC, Kaytor EN, Shih HM. Regulation of the expression of lipogenic
enzyme genes by carbohydrate. Annu Rev Nutr. 1997;17:405–33.
2. Zhao LF, Iwasaki Y, Zhe W, Nishiyama M, Taguchi T, Tsugita M, et al. Hormonal
regulation of acetyl-CoA carboxylase isoenzyme gene transcription. Endocr J.
2010;57:317–24.
3. Abu-Elheiga L, Wu H, Gu Z, Bressler R, Wakil SJ. Acetyl-CoA carboxylase
2-/- mutant mice are protected against fatty liver under high-fat,
high-carbohydrate dietary and de novo lipogenic conditions. J Biol Chem.
2012;287:12578–88.
4. Dorn C, Riener MO, Kirovski G, Saugspier M, Steib K, Weiss TS, et al.
Expression of fatty acid synthase in nonalcoholic fatty liver disease. Int J Clin
Exp Pathol. 2010;3:505–14.
5. Miyazaki M, Flowers MT, Sampath H, Chu K, Otzelberger C, Liu X, et al.
Hepatic stearoyl-CoA desaturase-1 deficiency protects mice from
carbohydrate-induced adiposity and hepatic steatosis. Cell Metab.
2007;6:484–96.
6. Shimano H. Novel qualitative aspects of tissue fatty acids related to
metabolic regulation: lessons from Elovl6 knockout. Prog Lipid Res.
2012;51:267–71.
7. Wendel AA, Cooper DE, Ilkayeva OR, Muoio DM, Coleman RA. Glycerol-3-
phosphate acyltransferase (GPAT)-1, but not GPAT4, incorporates newly
synthesized fatty acids into triacylglycerol and diminishes fatty acid
oxidation. J Biol Chem. 2013;288:27299–306.
8. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic
steatosis and insulin resistance: lessons from genetically engineered mice.
J Clin Invest. 2008;118:829–38.
9. Latasa MJ, Moon YS, Kim KH, Sul HS. Nutritional regulation of the fatty acid
synthase promoter in vivo: sterol regulatory element binding protein
functions through an upstream region containing a sterol regulatory
element. Proc Natl Acad Sci U S A. 2000;97:10619–24.
10. Ferre P, Foufelle F. Hepatic steatosis: a role for de novo lipogenesis and the
transcription factor SREBP-1c. Diabetes Obes Metab. 2010;12 Suppl 2:83–92.
11. Kersten S. Mechanisms of nutritional and hormonal regulation of
lipogenesis. EMBO Rep. 2001;2:282–6.
12. Shimano H, Shimomura I, Hammer RE, Herz J, Goldstein JL, Brown MS, et al.
Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice
homozygous for a targeted disruption of the SREBP-1 gene. J Clin Invest.
1997;100:2115–24.
13. Roberts R, Hodson L, Dennis AL, Neville MJ, Humphreys SM, Harnden KE,
et al. Markers of de novo lipogenesis in adipose tissue: associations with
small adipocytes and insulin sensitivity in humans. Diabetologia.
2009;52:882–90.
14. Savage DB, Choi CS, Samuel VT, Liu Z-X, Zhang D, Wang A, et al. Reversal of
diet-induced hepatic steatosis and hepatic insulin resistance by antisense
oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest.
2006;116:817–24.
15. Hudgins LC, Parker TS, Levine DM, Hellerstein MK. A dual sugar challenge
test for lipogenic sensitivity to dietary fructose. J Clin Endocrinol Metab.
2011;96:861–8.
16. Willy PJ, Umesono K, Ong ES, Evans RM, Heyman RA, Mangelsdorf DJ. LXR,
a nuclear receptor that defines a distinct retinoid response pathway. Genes
Dev. 1995;9:1033–45.17. Chen G, Liang G, Ou J, Goldstein JL, Brown MS. Central role for liver X
receptor in insulin-mediated activation of Srebp-1c transcription and
stimulation of fatty acid synthesis in liver. Proc Natl Acad Sci U S A.
2004;101:11245–50.
18. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, et al. Role of LXRs in
control of lipogenesis. Genes Dev. 2000;14:2831–8.
19. Joseph SB, Laffitte BA, Patel PH, Watson MA, Matsukuma KE, Walczak R, et al.
Direct and indirect mechanisms for regulation of fatty acid synthase gene
expression by liver X receptors. J Biol Chem. 2002;277:11019–25.
20. Klaunig JE, Goldblatt PJ, Hinton DE, Lipsky MM, Chacko J, Trump BF. Mouse
liver cell culture. I. Hepatocyte isolation. In Vitro. 1981;17:913–25.
21. BLIGH EG, DYER WJ. A rapid method of total lipid extraction and
purification. Can J Biochem Physiol. 1959;37:911–7.
22. Orlando V, Strutt H, Paro R. Analysis of chromatin structure by in vivo
formaldehyde cross-linking. Methods. 1997;11:205–14.
23. Naik SU, Wang X, Da Silva JS, Jaye M, Macphee CH, Reilly MP, et al.
Pharmacological activation of liver X receptors promotes reverse cholesterol
transport in vivo. Circulation. 2006;113:90–7.
24. Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards PA,
et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor
LXRα. Proc Natl Acad Sci U S A. 2000;97:12097–102.
25. Kennedy MA, Venkateswaran A, Tarr PT, Xenarios I, Kudoh J, Shimizu N, et al.
Characterization of the human ABCG1 gene: liver X receptor activates an
internal promoter that produces a novel transcript encoding an alternative
form of the protein. J Biol Chem. 2001;276:39438–47.
26. Oram JF, Lawn RM. ABCA1. The gatekeeper for eliminating excess tissue
cholesterol. J Lipid Res. 2001;42:1173–9.
27. Yoon G, Jung YD, Cheon SH. Cytotoxic allyl retrochalcone from the roots of
Glycyrrhiza inflata. Chem Pharm Bull (Tokyo). 2005;53:694–5.
28. Nomura T, Fukai T. Phenolic constituents of licorice (Glycyrrhiza species).
Fortschr Chem Org Naturst. 1998;73:1–158.
29. Kajiyama K, Demizu S, Hiraga Y, Kinoshita K, Koyama K, Takahashi K, et al.
Two prenylated retrochalcones from Glycyrrhiza inflata. Phytochemistry.
1992;31:3229–32.
30. Kolbe L, Immeyer J, Batzer J, Wensorra U, Dieck K, Mundt C, et al.
Anti-inflammatory efficacy of Licochalcone A: correlation of clinical
potency and in vitro effects. Arch Dermatol Res. 2006;298:23–30.
31. Funakoshi-Tago M, Nakamura K, Tsuruya R, Hatanaka M, Mashino T, Sonoda Y,
et al. The fixed structure of Licochalcone A by alpha, beta-unsaturated ketone
is necessary for anti-inflammatory activity through the inhibition of NF-kappaB
activation. Int Immunopharmacol. 2010;10:562–71.
32. Mi-Ichi F, Miyadera H, Kobayashi T, Takamiya S, Waki S, Iwata S, et al.
Parasite mitochondria as a target of chemotherapy: inhibitory effect of
licochalcone A on the Plasmodium falciparum respiratory chain. Ann N Y
Acad Sci. 2005;1056:46–54.
33. Messier C, Grenier D. Effect of licorice compounds licochalcone A, glabridin
and glycyrrhizic acid on growth and virulence properties of Candida
albicans. Mycoses. 2011;54:e801–6.
34. Rafi MM, Rosen RT, Vassil A, Ho CT, Zhang H, Ghai G, et al. Modulation of
bcl-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid.
Anticancer Res. 2000;20:2653–8.
35. Fu Y, Hsieh TC, Guo J, Kunicki J, Lee MY, Darzynkiewicz Z, et al. Licochalcone-A,
a novel flavonoid isolated from licorice root (Glycyrrhiza glabra), causes G2 and
late-G1 arrests in androgen-independent PC-3 prostate cancer cells. Biochem
Biophys Res Commun. 2004;322:263–70.
36. Kim SN, Bae SJ, Kwak HB, Min YK, Jung SH, Kim CH, et al. In vitro
and in vivo osteogenic activity of licochalcone A. Amino Acids.
2012;42:1455–65.
37. Quan HY, Kim SJ, Kim Do Y, Jo HK, Kim GW, Chung SH. Licochalcone A
regulates hepatic lipid metabolism through activation of AMP-activated
protein kinase. Fitoterapia. 2013;86:208–16.
38. Cagen LM, Deng X, Wilcox HG, Park EA, Raghow R, Elam MB. Insulin
activates the rat sterol-regulatory-element-binding protein 1c (SREBP-1c)
promoter through the combinatorial actions of SREBP, LXR, Sp-1 and NF-Y
cis-acting elements. Biochem J. 2005;385:207–16.
39. Costet P, Luo Y, Wang N, Tall AR. Sterol-dependent Transactivation of
theABC1 Promoter by the Liver X Receptor/Retinoid X Receptor. J Biol
Chem. 2000;275:28240–5.
40. Repa JJ, Turley SD, Lobaccaro J-MA, Medina J, Li L, Lustig K, et al. Regulation of
Absorption and ABC1-Mediated Efflux of Cholesterol by RXR Heterodimers.
Science. 2000;289:1524–9.
Oh et al. Chinese Medicine  (2015) 10:8 Page 8 of 841. Gelissen IC, Harris M, Rye KA, Quinn C, Brown AJ, Kockx M, et al. ABCA1 and
ABCG1 synergize to mediate cholesterol export to apoA-I. Arterioscler
Thromb Vasc Biol. 2006;26:534–40.
42. Wang N, Silver DL, Thiele C, Tall AR. ATP-binding Cassette Transporter A1
(ABCA1) Functions as a Cholesterol Efflux Regulatory Protein. J Biol Chem.
2001;276:23742–7.
43. Wang N, Lan D, Chen W, Matsuura F, Tall AR. ATP-binding cassette
transporters G1 and G4 mediate cellular cholesterol efflux to high-density
lipoproteins. Proc Natl Acad Sci U S A. 2004;101:9774–9.
44. Wagner BL, Valledor AF, Shao G, Daige CL, Bischoff ED, Petrowski M, et al.
Promoter-specific roles for liver X receptor/corepressor complexes in the
regulation of ABCA1 and SREBP1 gene expression. Mol Cell Biol.
2003;23:5780–9.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
